Evidence map›Paper›PMID 41864057›Full record

ArticleBreast (Edinburgh, Scotland)2026

Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.

Chiara Corti, Tianyu Li, Alyssa R Martin, Melissa E Hughes, Tonia Parker, Tyzaire S Duporte, Giuseppe Curigliano, Tari A King, Elizabeth A Mittendorf, Nancy U Lin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chiara CortiBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
Tianyu LiDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Alyssa R MartinBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Melissa E HughesBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA.
Tonia ParkerDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Tyzaire S DuporteDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Giuseppe CuriglianoDivision of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology (DIPO), University of Milan, Milan, Italy.
Tari A KingBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Elizabeth A MittendorfBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Nancy U LinBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Nabihah TayobDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Sara M TolaneyBreast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sara_tolaney@dfci.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPathologic complete response (pCR) after neoadjuvant treatment (NAT) is prognostic for recurrence-free survival (RFS) and overall survival (OS) in breast cancer (BC). We assessed prognostic factors for RFS and OS in patients with pCR compared to residual disease (RD) in HER2+ and triple-negative breast cancer (TNBC).

methodsWe retrospectively evaluated patients with early HER2+ BC or TNBC who underwent surgery following NAT at Dana-Farber Cancer Institute and who had data on pCR (ypT0/is, ypN0), RD, RFS, and OS. Clinical tumor size (cT), nodal status (cN), and subtype were assessed using Cox models and Kaplan-Meier methods (p < .05 significant).

results863 patients (median age 50.2, range 21.0-85.4) underwent surgery from 2016 to 2021, with a median follow-up of 3.5 years. Three-year RFS was 87% overall, 93% in HER2+, and 80% in TNBC cohorts. Among 374 pCR patients (43.3%), 3-year RFS was 98%, compared to 79% in 489 RD patients (56.7%). In HER2+ BC, 3-year RFS was 99% for pCR vs. 87% for RD, while in TNBC it was 97% for pCR vs. 72% for RD. Higher cT, positive cN, TNBC subtype, and RD were associated with poorer RFS and OS. In pCR, 3-year RFS was numerically higher in cT1-2 compared to cT3-4 and in cN0 compared to cN+ (not significant). In RD, higher cT, positive cN, and TNBC subtype remained associated with poorer outcomes. Multivariate analysis found no associations in pCR patients.

conclusionPatients experiencing pCR had better outcomes. cT, cN, and subtype were prognostic only in patients with RD.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyTriple Negative Breast NeoplasmsAdultAgedAged, 80 and overDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm, ResidualPathologic Complete ResponsePrognosisRetrospective StudiesYoung AdultERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerHER2NeoadjuvantOutcomesPathologic responseTriple negative

Identifiers

PMID41864057
PMCPMC13020001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.